A Novel Mutation of COL4A3 Presents a Different Contribution to Alport Syndrome and Thin Basement Membrane Nephropathy

2007 ◽  
Vol 27 (5) ◽  
pp. 538-544 ◽  
Author(s):  
Ping Hou ◽  
Yuqing Chen ◽  
Jiaxiang Ding ◽  
Guangtao Li ◽  
Hong Zhang
2020 ◽  
Vol 13 (6) ◽  
pp. 1025-1036 ◽  
Author(s):  
Andreas Matthaiou ◽  
Tsielestina Poulli ◽  
Constantinos Deltas

Abstract Background Patients heterozygous for COL4A3 or COL4A4 mutations show a wide spectrum of disease, extending from familial isolated microscopic haematuria, as a result of thin basement membranes (TBMs), to autosomal dominant Alport syndrome (ADAS) and end-stage renal disease (ESRD). Many patients are mentioned in the literature under the descriptive diagnosis of TBM nephropathy (TBMN), in which case it actually describes a histological finding that represents the carriers of autosomal recessive Alport syndrome (ARAS), a severe glomerulopathy, as most patients reach ESRD at a mean age of 25 years. Methods We performed a systematic literature review for patients with heterozygous COL4A3/A4 mutations with the aim of recording the spectrum and frequency of pathological features. We searched three databases (PubMed, Embase and Scopus) using the keywords ‘Autosomal Dominant Alport Syndrome’ OR ‘Thin Basement Membrane Disease’ OR ‘Thin Basement Membrane Nephropathy’. We identified 48 publications reporting on 777 patients from 258 families. Results In total, 29% of the patients developed chronic kidney disease (CKD) and 15.1% reached ESRD at a mean age of 52.8 years. Extrarenal features and typical Alport syndrome (AS) findings had a low prevalence in patients as follows: hearing loss, 16%; ocular lesions, 3%; basement membrane thickening, 18.4%; and podocyte foot process effacement, 6.9%. Data for 76 patients from 54 families emphasize extensive inter- and intrafamilial heterogeneity, with age at onset of ESRD ranging between 21 and 84 years (mean 52.8). Conclusions The analysis enabled a comparison of the clinical course of patients with typical ARAS or X-linked AS with those with heterozygous COL4A mutations diagnosed with TBMN or ADAS. Despite the consequence of a potential ascertainment bias, an important outcome is that TBM poses a global high risk of developing severe CKD, over a long follow-up, with a variable spectrum of other findings. The results are useful to practicing nephrologists for better evaluation of patients.


2014 ◽  
Vol 35 (5) ◽  
pp. 345-350 ◽  
Author(s):  
Shinichi OKADA ◽  
Sumire INAGA ◽  
Koichi KITAMOTO ◽  
Yasuo KAWABA ◽  
Hironobu NAKANE ◽  
...  

2016 ◽  
pp. 499-514 ◽  
Author(s):  
Michelle N. Rheault ◽  
Clifford E. Kashtan

2017 ◽  
Vol 71 ◽  
pp. 73-81
Author(s):  
Anna Moczulska ◽  
Joanna Walkosz ◽  
Estera Zarębska ◽  
Mateusz Mleczko ◽  
Katarzyna Zachwieja ◽  
...  

2013 ◽  
Vol 24 (3) ◽  
pp. 364-375 ◽  
Author(s):  
Judy Savige ◽  
Martin Gregory ◽  
Oliver Gross ◽  
Clifford Kashtan ◽  
Jie Ding ◽  
...  

2017 ◽  
Vol 39 (2) ◽  
pp. 208-214 ◽  
Author(s):  
Yan Chen ◽  
Deb Colville ◽  
Francesco Ierino ◽  
Andrew Symons ◽  
Judy Savige

Sign in / Sign up

Export Citation Format

Share Document